Dr. Brian Park is a fellowship-trained head and neck oncologic surgeon and otolaryngologist based at Mass. Eye and Ear, Newton-Wellesley. He earned his undergraduate degree from Massachusetts Institute of Technology and his medical degree from State University of New York Upstate Medical University. He stayed there to complete his general surgery internship and residency in otolaryngology—head and neck surgery. Subsequently, he completed his fellowship in head and neck oncologic surgery at the University of Pittsburgh Medical Center. Now, he is an Instructor in Otolaryngology at Harvard Medical School.
Board-certified in otolaryngology, Dr. Park serves as the director of the Multidisciplinary Head and Neck Tumor Board for the Vernon Cancer Center at Newton-Wellesley Hospital (NWH), a collaboration with Massachusetts General Hospital's Department of Oncology. This center will be soon renamed as the MGH Cancer Center at NWH. Dr. Park is an associate member of our Division of Head and Neck Surgical Oncology. He is a member of many national otolaryngology organizations and has published a number of peer-reviewed articles in the field. He also has his Masters in Public Health, concentrated in epidemiology and biostatistics, from Boston University School of Public Health.
Dr. Park’s clinical interests include head and neck cancer surgery, thyroid surgery, salivary gland surgery, and nasal and sinus surgery.
Molecular changes in the multistage pathogenesis of head and neck cancer. Park BJ, Chiosea SI, Grandis JR. In: Srivastava S, Grizzle WE, editors. Molecular pathology of early cancer (2nd ed). Cancer Biomark. 2010;9(1-6):325-39.
Papillary thyroid cancer: Controversies in the management of neck metastasis. Davidson HC, Park BJ, Johnson JT. Laryngoscope. 2008 Dec;118(12):2161-65.
Oculoauriculovertebral spectrum in two siblings. Park BJ, Tatum SA. International Journal of Pediatric Otorhinolaryngology Extra. 2007;2(3):161-164.
Association of Lbc Rho guanine nucleotide exchange factor with alpha-catenin-related protein, alpha-catulin/CTNNAL1, supports serum response factor activation. Park B, Nguyen NT, Dutt P, Merdek KD, Bashar M, Sterpetti P, Tosolini A, Testa JR, Toksoz D. Journal of Biological Chemistry. 2002 Nov 22;277(47):45361-70.
Activation of the Lbc Rho exchange factor proto-oncogene by truncation of an extended C terminus that regulates transformation and targeting. Sterpetti P, Hack AA, Bashar MP, Park B, Cheng SD, Knoll JH, Urano T, Feig LA, Toksoz D. Molecular & Cellular Biology. 1999 Feb;19(2):1334-45.
A complete list of research publications can be seen at www.pubmed.gov.